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At the same time, verbal cognitive function was assessed with the California Verbal 
Learning Test (CVLT) and the Verbal Fluency test (VF). The Clinical Global Impres-
sion-Severity (CGI-S) was assessed as well at the same visits. Statistical analysis was 
done using SAS 9.2 with the PROC MIXED module for mixed effects repeated mea-
sures analysis. RESULTS: A mixed models analyses on the QLESQ scores showed 
signiﬁ cant effects for CGI-S in all subscores but “ school “ (p = 0,1485) and for the 
verbal cognitive measures only in subscores “leisure “ for CVLT-LTFR (p = 0,0002). 
CONCLUSIONS: The observed difference over time in QLESQ values is dependent 
on the CGI-S score which contributes mostly to the prediction of the QLESQ outcome. 
Verbal cognitive outcome was not predictive . These ﬁ ndings are not in agreement 
with other publications reporting an independent contribution of both measures on 
quality of life. As the study was open-label, interpretation of the results should be 
approached with some caution.
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OBJECTIVES: The QUALITY study evaluated Quality-of-Life in schizophrenic 
patients treated with atypical antipsychotics (AAPs) in the ambulatory setting. 
METHODS: Patients (18–65 years-old) diagnosed with schizophrenia and had started 
treatment with one AAP before visit-1 (minimum: 4-weeks, maximum: 8-weeks) were 
enrolled into this Belgian study. At visit-1 patients’ demographics and medical history 
were recorded with follow-up visits after 3-, 6- and 9-months. At each visit, patients 
completed the Subjective Well-being under Neuropletic treatment short form (SWN-
K), while investigators assessed the Positive and Negative Symptom Scale (PANSS-8) 
and the Global Assessment of Functioning (GAF). RESULTS: A total of 121 patients 
(mean age 36.7 ± 10.8, 75.2% male) were enrolled with the main AAP treatments 
risperidone (31.4%), apripirazole (23.1%), quetiapine (20.7%). At baseline, the asso-
ciations between the SWN-K subscales and age, gender, positive/negative PANSS-
scores, Schizophrenia-subtype or treatment-subgroups were small. Mental-functioning 
and physical-functioning subscales were signiﬁ cantly correlated with negative PANSS-
scores, as was the emotional-regulation subscale with gender. The majority of changes 
from baseline in the SWN-K subscale scores were between −0.5 and +0.5 (range: −1.8 
to 1.6). Most mean changes were positive, suggesting that patients felt better compared 
to baseline. PANSS-8-score changes were slightly negative, suggesting decreases in 
symptom severity. 57.5% of patients showed symptom remission (PANSS-8-score ≤ 
3 after 6 months-of-treatment).GAF scores increased (study end: 8.2 ± 16.0) indicating 
improvement in the patient’s global functioning. By the study end, the number of 
hospitalizations and addictive substance use had decreased. Patients with more severe 
negative symptoms considered their mental- and physical-functioning better and men 
were more satisﬁ ed than women with their emotional-regulation. Few patients had 
sufﬁ cient disease insight; most patients had a vague notion or did not see that they 
were ill. CONCLUSIONS: The patients’ well-being seemed to improve slightly during 
the study without differences between the treatments. Patients having more severe 
negative symptoms considered their mental and physical functioning better at the 
study end.
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OBJECTIVES: Mood disorders are generally associated with a high level of productiv-
ity loss and a substantial economic burden. The aim of this study was to measure the 
impact of mood disorders on productivity in terms of absence from work, at-work 
productivity loss, and job performance among patients in the The Netherlands. 
METHODS: Patients meeting DSM-IV criteria for depressive disorder, dysthymic 
disorder, panic disorder (with or without agoraphobia), social phobia and generalised 
anxiety disorder were included from a large naturalistic trial in 7 Dutch mental health 
care centres. The short form of the Health and Labour Questionnaire (SF-HLQ) was 
used to assess absenteeism (days absent from work), presenteeism (at-work productiv-
ity loss) and job performance (on a 3-point scale ranging from ‘not impeded’ to ‘very 
much impeded’). ANOVA analyses and t-tests were performed to explore differences 
between socio-demographic groups. RESULTS: Of the total 702 patients, two thirds 
were in paid employment. Over 3 months, 55% reported long-term absenteeism (>2 
weeks), with a mean of 73 work days lost per patient, and 13% patients reported a 
shorter-term absenteeism (<2 weeks), with a mean of 33 work days lost per patient. 
Women were absent from work for a longer (99 days) than men (46 days) (P < 0.005). 
Presenteeism accounted for a 12% productivity loss in terms of working time lost. 
The number of days at work while impeded by health problems was numerically 
higher in men than in women (7.4 vs. 5.6, p > 0.05). Overall, 31% of the patients 
had difﬁ culties in job performance when at work. CONCLUSIONS: Mood disorders 
are associated with impairment of patients’ productivity in terms of absence from 
work, presenteeism and difﬁ culties in job performance The study demonstrated a 
tendency towards lower absenteeism and higher presenteeism in men compared to 
women. 
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OBJECTIVES: The objective of this study is to analyze antidepressants and anxiolytics 
drugs usage (ATC subgroups: N06A and N05B) in two mid European, neighbouring 
countries, Croatia and Slovenia, for the 9-year period, from 2000 to 2008. Further, 
the aim was to identify the generic drugs usage in each country, the price for DDD 
for original and generic drugs, and to identify the most prescribed drugs in each drug 
group. METHODS: The data have been obtained from the International Medical 
Statistics database for Croatia and Slovenia. Drugs usage is presented in deﬁ ned daily 
doses per 1000 inhabitants per day (DDD/1000) according to the WHO Methodology. 
Financial expenditure data are presented in Euros. An average cost per DDD was 
calculated for each drug group. RESULTS: In 2008, the total usage of antidepressants 
was higher in Slovenia (42.7 DDD/1000 inhabitants/day) than in Croatia (22 
DDD/1000 inhabitants/day), and it increased in both countries during the investigated 
period. The total usage of anxiolytics is more than 3 times higher in Croatia (67.4 
DDD/1000 inhabitants/day) than in Slovenia (22.2 DDD/1000/inhabitants/day). The 
total usage of anxiolytics decreased in Slovenia in 2008 in comparison with prescrip-
tions in 2000, while it increased in Croatia for 44.3% during the same period. The 
rate of generic prescriptions among antidepressants during the investigated period was 
higher in Croatia, i.e. in Croatia 73.6% of all prescribed antidepressants were generics 
in 2008, while in Slovenia 33.5%. CONCLUSIONS: Drugs prescription patterns are 
different comparing Croatia and Slovenia. a possible reason for relatively higher usage 
of anxiolytics and lower usage of antidepressants in Croatia could be depression 
treatment with anxiolytics. This indicates the need for a more thorough analysis and 
the introduction of national drugs guidelines for rational prescribing, monitoring and 
evaluation especially anxiolytics. Although the generic drugs usage in the mentioned 
groups is relatively high, it should be further supported and promoted.
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OBJECTIVES: Antipsychotic medicines are commonly prescribed to elderly patients. 
These patients are at an increased risk of adverse drug events because of age-related 
pharmacodynamic and pharmacokinetic changes. The primary aim of the study was 
to determine antipsychotic prescribing patterns and cost to patients aged 60 years and 
older in a private health care sector primary care patient population in 2008 and 2009. 
METHODS: A retrospective, exposure-cohort drug utilization study was conducted 
on prescription data of a pharmacy group in South Africa for 2008 and 2009. No 
diagnoses were available. All records for antipsychotics (MIMS category 1.5) for 
patients 60 years and older were extracted for analysis. RESULTS: A total of 1 800 
patients in 2008 and 3 086 patients in 2009 received 7 877 and 14 538 antipsychotic 
products at a sales value of R2 785 896 and R4 928 127, respectively. The average cost 
per antipsychotic product was R353.67 in 2008 and R338.98 in 2009. Most patients 
were female (61.78% in 2008 and 57.87% in 2009). Tablets were the preferred dosage 
form. Risperidone (37.55% in 2008, and 38.20% in 2009), quetiapine (27.56% and 
28.88%) and olanzapine (10.91% and 10.24%) together accounted for more than 
75% of antipsychotics prescribed to the elderly. a high percentage of atypical antipsy-
chotics (84.23% in 2008 and 85.14% in 2009) were prescribed. Differences were 
observed between 2008 and 2009 with respect to the prescribing frequency of the 
atypical antipsychotics (chi2 = 32.624; d.f. = 6; p < 0.0001). CONCLUSIONS: Pre-
scribing patterns were relatively similar in both years. The dosages and duration of 
treatment of antipsychotics should be investigated in relation to the diagnoses for 
which they are prescribed. It is recommended that diagnoses be included in databases 
and also that qualitative studies be conducted to determine possible side effects expe-
rienced by patients.
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OBJECTIVES: England has 152 Primary Care Trust (PCT) each having its own 
characteristics, and prescription patterns. As a consequence, PCT formulary lists 
differ, creating an additional hurdle for patient access to innovative medicines, often 
referred to as the post-code lottery. The objective of this study was to segment these 
PCTs in groups with homogeneous attitudes towards patient access for innovative 
drugs in Mental Health (MH) using a clustering analysis. METHODS: We collected 
all available information about the PCTs through public sources and the OneKey + 
database. We identiﬁ ed 62 variables per PCT and classiﬁ ed them in 5 groups: proﬁ le 
